Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Free Cash Flow (2022 - 2025)

Bioregenx (BRGX) has 4 years of Free Cash Flow data on record, last reported at -$77564.0 in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 148.63% year-over-year to -$77564.0; the TTM value through Sep 2025 reached -$48025.0, up 93.58%, while the annual FY2024 figure was -$513538.0, 66.1% up from the prior year.
  • Free Cash Flow reached -$77564.0 in Q3 2025 per BRGX's latest filing, down from $3205.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $37695.0 in Q1 2025 and bottomed at -$649161.0 in Q2 2023.
  • Average Free Cash Flow over 4 years is -$141993.1, with a median of -$33110.0 recorded in 2022.
  • Peak YoY movement for Free Cash Flow: tumbled 5528.46% in 2023, then skyrocketed 112.84% in 2025.
  • A 4-year view of Free Cash Flow shows it stood at -$4364.0 in 2022, then crashed by 5528.46% to -$245626.0 in 2023, then skyrocketed by 95.37% to -$11361.0 in 2024, then crashed by 582.72% to -$77564.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$77564.0 in Q3 2025, $3205.0 in Q2 2025, and $37695.0 in Q1 2025.